GSK, iTeos Therapeutics to co-develop and co-commercialise cancer drug
TIGIT, a part of the CD226 checkpoint axis, has shown potential as a promising target for the next generation of immuno-oncology therapies based on preclinical data and a
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted priority medicines (PRIME) designation to AbelZeta Pharma’s C-CAR168.
Pharmaceutical company Indivior has collaborated with French biotechnology company Aelis Farma to advance the clinical development of a treatment for cannabis use disorder (CUD) and cannabis-induced psychosis (CIP).